The tumor microenvironment in prostate cancer: elucidating molecular pathways for therapy development

References

• American Cancer SocietyCancer Facts and Figures 2010Atlanta, GAAmerican Cancer Society2010
   Google Scholar
• JemalASiegelRXuJWardECancer statistics, 2010CA Cancer J Clin201060527730020610543
   PubMed Web of Science ®Google Scholar
• FerlayJParkinDMSteliarova-FoucherEEstimates of cancer incidence and mortality in Europe in 2008Eur J Cancer201046476578120116997
   PubMed Web of Science ®Google Scholar
• RoehrbornCGBlackLKThe economic burden of prostate cancerBJU Int2011108680681321884356
   PubMed Web of Science ®Google Scholar
• SiegelRWardEBrawleyOJemalACancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deathsCA Cancer J Clin201161421223621685461
   PubMed Web of Science ®Google Scholar
• WalczakJRCarducciMAProstate cancer: a practical approach to current management of recurrent diseaseMayo Clin Proc200782224324917290734
   PubMed Web of Science ®Google Scholar
• ChiKNBjartellADearnaleyDCastration-resistant prostate cancer: from new pathophysiology to new treatment targetsEur Urol200956459460519560857
   PubMed Web of Science ®Google Scholar
• SturgeJCaleyMPWaxmanJBone metastasis in prostate cancer: emerging therapeutic strategiesNat Rev Clin Oncol20118635736821556025
   PubMed Web of Science ®Google Scholar
• HenshallSMQuinnDILeeCSAltered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancerCancer Res200161242342711212224
   PubMed Web of Science ®Google Scholar
• MassieCELynchARamos-MontoyaAThe androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesisEMBO J201130132719273321602788
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer NetworkClinical practice guidelines in oncology: prostate cancer guidelines (version 2. 2011)2011 Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#siteAccessed November 20, 2010
   Google Scholar
• SerugaBOcanaATannockIFDrug resistance in metastatic castration-resistant prostate cancerNat Rev Clin Oncol201181122320859283
   PubMed Web of Science ®Google Scholar
• MostaghelEAPageSTLinDWIntraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancerCancer Res200767105033504117510436
   PubMed Web of Science ®Google Scholar
• MontgomeryRBMostaghelEAVessellaRMaintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growthCancer Res200868114447445418519708
   PubMed Web of Science ®Google Scholar
• EfstathiouELogothetisCJA new therapy paradigm for prostate cancer founded on clinical observationsClin Cancer Res20101641100110720145177
   PubMed Web of Science ®Google Scholar
• AngJEOlmosDde BonoJSCYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancerBr J Cancer2009100567167519223900
   PubMed Web of Science ®Google Scholar
• de BonoJSLogothetisCJMolinaAAbiraterone and increased survival in metastatic prostate cancerN Engl J Med2011364211995200521612468
   PubMed Web of Science ®Google Scholar
• TannockIFde WitRBerryWRDocetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancerN Engl J Med2004351151502151215470213
   PubMed Web of Science ®Google Scholar
• de BonoJSOudardSOzgurogluMPrednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trialLancet201037697471147115420888992
   PubMed Web of Science ®Google Scholar
• KantoffPWHiganoCSShoreNDSipuleucel-T immunotherapy for castration-resistant prostate cancerN Engl J Med2010363541142220818862
   PubMed Web of Science ®Google Scholar
• SmallEJde BonoJSProstate cancer: evolution or revolution?J Clin Oncol201129273595359821859996
   PubMed Web of Science ®Google Scholar
• JossonSMatsuokaYChungLWZhauHEWangRTumor-stroma co-evolution in prostate cancer progression and metastasisSemin Cell Dev Biol2010211263219948237
   PubMed Web of Science ®Google Scholar
• JoyceJATherapeutic targeting of the tumor microenvironmentCancer Cell20057651352015950901
   PubMed Web of Science ®Google Scholar
• TuxhornJAAyalaGERowleyDRReactive stroma in prostate cancer progressionJ Urol200116662472248311696814
   PubMed Web of Science ®Google Scholar
• KarlouMTzelepiVEfstathiouETherapeutic targeting of the prostate cancer microenvironmentNat Rev Urol20107949450920818327
   PubMed Web of Science ®Google Scholar
• DudleyACShihSCCliffeARHidaKKlagsbrunMAttenuated p53 activation in tumour-associated stromal cells accompanies decreased sensitivity to etoposide and vincristineBr J Cancer200899111812518594537
   PubMed Web of Science ®Google Scholar
• HillRSongYCardiffRDVan DykeTSelective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesisCell200512361001101116360031
   PubMed Web of Science ®Google Scholar
• KiarisHChatzistamouITrimisGFrangou-PlemmenouMPafiti-KondiAKalofoutisAEvidence for nonautonomous effect of p53 tumor suppressor in carcinogenesisCancer Res20056551627163015753354
   PubMed Web of Science ®Google Scholar
• JohanssonJEHolmbergLJohanssonSBergstromRAdamiHOFifteen-year survival in prostate cancer. A prospective, population-based study in SwedenJAMA199727764674719020270
   PubMed Web of Science ®Google Scholar
• CunhaGRHaywardSWDahiyaRFosterBASmooth muscle-epithelial interactions in normal and neoplastic prostatic developmentActa Anat (Basel)1996155163728811117
   PubMedGoogle Scholar
• ChungLWZhauHERoJYMorphologic and biochemical alterations in rat prostatic tumors induced by fetal urogenital sinus mesenchymeProstate19901721651742399192
   PubMed Web of Science ®Google Scholar
• RowleyDRWhat might a stromal response mean to prostate cancer progression?Cancer Metastasis Rev 1998–1999174411419
   Google Scholar
• De WeverODemetterPMareelMBrackeMStromal myofibroblasts are drivers of invasive cancer growthInt J Cancer2008123102229223818777559
   PubMed Web of Science ®Google Scholar
• DesmouliereAGuyotCGabbianiGThe stroma reaction myofibroblast: a key player in the control of tumor cell behaviorInt J Dev Biol2004485–650951715349825
   PubMed Web of Science ®Google Scholar
• PowellDWMyofibroblasts: paracrine cells important in health and diseaseTrans Am Clin Climatol Assoc200011127129310881346
   PubMedGoogle Scholar
• AlbiniASpornMBThe tumour microenvironment as a target for chemopreventionNat Rev Cancer20077213914717218951
   PubMed Web of Science ®Google Scholar
• TuxhornJAAyalaGESmithMJSmithVCDangTDRowleyDRReactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodelingClin Cancer Res2002892912292312231536
   PubMed Web of Science ®Google Scholar
• BarclayWWWoodruffRDHallMCCramerSDA system for studying epithelial-stromal interactions reveals distinct inductive abilities of stromal cells from benign prostatic hyperplasia and prostate cancerEndocrinology20051461131815471963
   PubMed Web of Science ®Google Scholar
• OlumiAFGrossfeldGDHaywardSWCarrollPRTlstyTDCunhaGRCarcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epitheliumCancer Res199959195002501110519415
   PubMed Web of Science ®Google Scholar
• HayashiNCunhaGRMesenchyme-induced changes in the neoplastic characteristics of the Dunning prostatic adenocarcinomaCancer Res19915118492449301893381
   PubMed Web of Science ®Google Scholar
• MiyakeHHaraIKurahashiTInoueTAEtoHFujisawaMQuantitative detection of micrometastases in pelvic lymph nodes in patients with clinically localized prostate cancer by real-time reverse transcriptase-PCRClin Cancer Res20071341192119717317829
   PubMed Web of Science ®Google Scholar
• BubendorfLSchopferAWagnerUMetastatic patterns of prostate cancer: an autopsy study of 1589 patientsHum Pathol200031557858310836297
   PubMed Web of Science ®Google Scholar
• ChengLBergstralhEJChevilleJCCancer volume of lymph node metastasis predicts progression in prostate cancerAm J Surg Pathol19982212149115009850175
   PubMed Web of Science ®Google Scholar
• Pontes-JuniorJReisSTDall’OglioMEvaluation of the expression of integrins and cell adhesion molecules through tissue microarray in lymph node metastases of prostate cancerJ Carcinog20098319240373
   PubMedGoogle Scholar
• HayEDAn overview of epithelio-mesenchymal transformationActa Anat (Basel)199515418208714286
   PubMedGoogle Scholar
• GuarinoMRubinoBBallabioGThe role of epithelial-mesenchymal transition in cancer pathologyPathology200739330531817558857
   PubMed Web of Science ®Google Scholar
• DattaKMudersMZhangHTindallDJMechanism of lymph node metastasis in prostate cancerFuture Oncol20106582383620465393
   PubMed Web of Science ®Google Scholar
• CaoYOpinion: emerging mechanisms of tumour lymphangiogenesis and lymphaticmetastasisNat Rev Cancer20055973574316079909
   PubMed Web of Science ®Google Scholar
• KoenemanKSYeungFChungLWOsteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environmentProstate199939424626110344214
   PubMed Web of Science ®Google Scholar
• LecroneVLiWDevollRELogothetisCFarach-CarsonMCCalcium signals in prostate cancer cells: specific activation by bone-matrix proteinsCell Calcium2000271354210726209
   PubMed Web of Science ®Google Scholar
• ThomasRTrueLDBassukJALangePHVessellaRLDifferential expression of osteonectin/SPARC during human prostate cancer progressionClin Cancer Res2000631140114910741745
   PubMed Web of Science ®Google Scholar
• CastellanoDSepulvedaJMGarcia-EscobarIRodriguez-AntolinASundlovACortes-FunesHThe role of RANK-ligand inhibition in cancer: the story of denosumabOncologist201116213614521285392
   PubMed Web of Science ®Google Scholar
• KellerETBrownJProstate cancer bone metastases promote both osteolytic and osteoblastic activityJ Cell Biochem200491471872914991763
   PubMed Web of Science ®Google Scholar
• LangSHMillerWRHabibFKStimulation of human prostate cancer cell lines by factors present in human osteoblast-like cells but not in bone marrowProstate19952752872937479396
   PubMed Web of Science ®Google Scholar
• BlaszczykNMasriBAMawjiNROsteoblast-derived factors induce androgen-independent proliferation and expression of prostate-specific antigen in human prostate cancer cellsClin Cancer Res20041051860186915014041
   PubMed Web of Science ®Google Scholar
• LiYSikesRAMalaebBSOsteoblasts can stimulate prostate cancer growth and transcriptionally down-regulate PSA expression in cell line modelsUrol Oncol201129680280820451417
   PubMed Web of Science ®Google Scholar
• SungSYHsiehCLLawACoevolution of prostate cancer and bone stroma in three-dimensional coculture: implications for cancer growth and metastasisCancer Res2008682399961000319047182
   PubMed Web of Science ®Google Scholar
• LuYZhangJDaiJOsteoblasts induce prostate cancer proliferation and PSA expression through interleukin-6-mediated activation of the androgen receptorClin Exp Metastasis200421539940815672864
   PubMed Web of Science ®Google Scholar
• ReichertJCQuentVMBurkeLJStansfieldSHClementsJAHutmacherDWMineralized human primary osteoblast matrices as a model system to analyse interactions of prostate cancer cells with the bone microenvironmentBiomaterials201031317928793620688384
   PubMed Web of Science ®Google Scholar
• ParkerCHeinrichDO’SullivanJMOverall survival benefit of radium-223 chloride (Alpharadin™) in the treatment of patients with symptomatic bone metastases in castration-resistant prostate cancer (CRPC): a phase III randomized trial (ALSYMPCA)Paper presented at: 2011 European Multidisciplinary Cancer CongressSeptember 24–27, 2011Stockholm, Sweden
   Google Scholar
• BissellMJRadiskyDPutting tumours in contextNat Rev Cancer200111465411900251
   PubMed Web of Science ®Google Scholar
• GoelHLLiJKoganSLanguinoLRIntegrins in prostate cancer progressionEndocr Relat Cancer200815365766418524948
   PubMed Web of Science ®Google Scholar
• MitraSKSchlaepferDDIntegrin-regulated FAK-Src signaling in normal and cancer cellsCurr Opin Cell Biol200618551652316919435
   PubMed Web of Science ®Google Scholar
• ThalmannGNRheeHSikesRAHuman prostate fibroblasts induce growth and confer castration resistance and metastatic potential in LNCaP CellsEur Urol201058116217119747763
   PubMed Web of Science ®Google Scholar
• Abate-ShenCShenMMFGF signaling in prostate tumorigenesis – new insights into epithelial-stromal interactionsCancer Cell200712649549718068626
   PubMed Web of Science ®Google Scholar
• DuttSSGaoACMolecular mechanisms of castration-resistant prostate cancer progressionFuture Oncol2009591403141319903068
   PubMed Web of Science ®Google Scholar
• PientaKJBradleyDMechanisms underlying the development of androgen-independent prostate cancerClin Cancer Res20061261665167116551847
   PubMed Web of Science ®Google Scholar
• AntonarakisESArmstrongAJEvolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancerProstate Cancer Prostatic Dis201114319220521577234
   PubMed Web of Science ®Google Scholar
• SternbergCNDumezHVan PoppelHDocetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancerAnn Oncol20092071264126919297314
   PubMed Web of Science ®Google Scholar
• CarducciMASaadFAbrahamssonPAA phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancerCancer200711091959196617886253
   PubMed Web of Science ®Google Scholar
• VishnuPTanWWUpdate on options for treatment of metastatic castration-resistant prostate cancerOnco Targets Ther20103395120616956
   PubMed Web of Science ®Google Scholar
• AstraZeneca halts phase III trial of ZIBOTENTAN in non-metastatic castrate resistant prostate cancer [press release]LondonAstraZeneca272011
   Google Scholar
• FizaziKCarducciMSmithMDenosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind studyLancet2011377976881382221353695
   PubMed Web of Science ®Google Scholar
• FizaziKThe role of Src in prostate cancerAnn Oncol200718111765177317426060
   PubMed Web of Science ®Google Scholar
• SaadFSrc as a therapeutic target in men with prostate cancer and bone metastasesBJU Int2009103443444019154462
   PubMed Web of Science ®Google Scholar
• MendirattaPMostaghelEGuinneyJGenomic strategy for targeting therapy in castration-resistant prostate cancerJ Clin Oncol200927122022202919289629
   PubMed Web of Science ®Google Scholar
• AraujoJCMathewPArmstrongAJDasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1–2 studyCancer20121181637121976132
   PubMed Web of Science ®Google Scholar
• Bristol-Myers SquibbRandomized study comparing docetaxel plus dasatinib to docetaxel plus placebo in castration-resistant prostate cancer (READY)ClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2008 [updated April 30, 2012]. Available from: http://clinicaltrials.gov/show/NCT00744497. NLM Identifier: NCT00744497Accessed December 21, 2011.
   Google Scholar
• DanielpourDFunctions and regulation of transforming growth factor-beta (TGF-beta) in the prostateEur J Cancer200541684685715808954
   PubMed Web of Science ®Google Scholar
• BhowmickNAChytilAPliethDTGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epitheliaScience2004303565984885114764882
   PubMed Web of Science ®Google Scholar
• JonesEPuHKyprianouNTargeting TGF-beta in prostate cancer: therapeutic possibilities during tumor progressionExpert Opin Ther Targets200913222723419236240
   PubMed Web of Science ®Google Scholar
• VeronaEVElkahlounAGYangJBandyopadhyayAYehITSunLZTransforming growth factor-beta signaling in prostate stromal cells supports prostate carcinoma growth by up-regulating stromal genes related to tissue remodelingCancer Res200767125737574617575140
   PubMed Web of Science ®Google Scholar
• SongKWangHKrebsTLKimSJDanielpourDAndrogenic control of transforming growth factor-beta signaling in prostate epithelial cells through transcriptional suppression of transforming growth factor-beta receptor IICancer Res200868198173818218829577
   PubMed Web of Science ®Google Scholar
• MuellerMMFusenigNEFriends or foes – bipolar effects of the tumour stroma in cancerNat Rev Cancer200441183984915516957
   PubMed Web of Science ®Google Scholar
• MackayHJBuckanovichRJHirteHA phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II ConsortiaGynecol Oncol2012125113614022138373
   PubMed Web of Science ®Google Scholar
• ColomboNMangiliGMammolitiSA phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascitesGynecol Oncol20121251424722112608
   PubMed Web of Science ®Google Scholar
• de GrootJFLambornKRChangSMPhase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium studyJ Clin Oncol201129192689269521606416
   PubMed Web of Science ®Google Scholar
• TwardowskiPStadlerWMFrankelPPhase II study of aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium TrialUrology201076492392620646741
   PubMed Web of Science ®Google Scholar
• Sanofi-Aventis; Regeneron PharmaceuticalsAflibercept in combination with docetaxel in metastatic androgen independent prostate cancer (VENICE)ClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2007 [updated April 30, 2012]. Available from: http://clinicaltrials.gov/show/NCT00519285. NLM Identifier: NCT00519285Accessed December 21, 2011
   Google Scholar
• Van CutsemETaberneroJLakomyRIntravenous (IV) aflibercept versus placebo in combination with irinotecan/5-FU (FOLFIRI) for second-line treatment of metastatic colorectal cancer (mCRC): results of a multinational phase III trial (EFC10262-VELOUR) [abstract]Ann Oncol201122Suppl 5v18
   Google Scholar
• Van CutsemEPrenenHGuillen-PonceCA phase I/II, open-label, randomised study of BIBF 1120 plus mFOLFOX6 compared to bevacizumab plus mFOLFOX6 in patients with metastatic colorectal cancerPaper presented at: 2011 European Multidisciplinary Cancer Congress2011 September 23–27Stockholm, Sweden.
   Google Scholar
• AdelergDKarakunnelJJGulleyJLA phase II study of cediranib in post-docetaxel castration-resistant prostate cancerPaper presented at: American Society of Clinical Oncology 2010 Genitourinary Cancers SymposiumMarch 5–7, 2010San Francisco, CA.
   Google Scholar
• DalgleishAGalustianCThe potential of immunomodulatory drugs in the treatment of solid tumorsFuture Oncol2010691479148420919830
   PubMed Web of Science ®Google Scholar
• Celgene to discontinue docetaxel and prednisone plus lenalidomide phase III trial on CRPC [press release]BoudryCelgene International Sarl11232011
   Google Scholar
• ZarnegarRMichalopoulosGKThe many faces of hepatocyte growth factor: from hepatopoiesis to hematopoiesisJ Cell Biol19951295117711807775566
   PubMed Web of Science ®Google Scholar
• PeruzziBBottaroDPTargeting the c-Met signaling pathway in cancerClin Cancer Res200612123657366016778093
   PubMed Web of Science ®Google Scholar
• JiangWGHepatocyte growth factor and the hepatocyte growth factor receptor signalling complex as targets in cancer therapiesCurr Oncol2007142666917576468
   PubMedGoogle Scholar
• CaoBSuYOskarssonMNeutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal modelsProc Natl Acad Sci U S A200198137443744811416216
   PubMed Web of Science ®Google Scholar
• DaiYSiemannDWBMS-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitroMol Cancer Ther2010961554156120515943
   PubMed Web of Science ®Google Scholar
• HussainMSmithMRSweeneyCCabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): results from a phase II randomized discontinuation trial [abstract]J Clin Oncol201129 Suppl451622025164
   PubMed Web of Science ®Google Scholar
• Di LorenzoGBuonerbaCKantoffPWImmunotherapy for the treatment of prostate cancerNat Rev Clin Oncol20118955156121606971
   PubMed Web of Science ®Google Scholar
• BanderNHYaoDLiuHMHC class I and II expression in prostate carcinoma and modulation by interferon-alpha and -gammaProstate19973342332399397194
   PubMed Web of Science ®Google Scholar
• YangLPangYMosesHLTGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progressionTrends Immunol201031622022720538542
   PubMed Web of Science ®Google Scholar
• MercaderMBodnerBKMoserMTT cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancerProc Natl Acad Sci U S A20019825145651457011734652
   PubMed Web of Science ®Google Scholar
• MD Anderson Cancer Center, Bristol-Myers SquibbIpilimumab + androgen deprivation therapy in prostate cancerClinicalTrials gov [website on the Internet]Bethesda, MDUS National Library of Medicine2011 [updated April 11, 2012]. Available from: http://clinicaltrials.gov/show/NCT01377389. NLM Identifier: NCT01377389Accessed December 21, 2011
   Google Scholar
• OHSU Knight Cancer InstituteNational Cancer Institute Ipilimumab in combination with androgen suppression therapy in treating patients with metastatic hormone-resistant prostate cancerClinicalTrialsgov [website on the Internet]Bethesda, MDUS National Library of Medicine2011 [updated March 22, 2012]. Available from: http://clinicaltrials.gov/show/NCT01498978. NLM Identifier: NCT01498978Accessed December 21, 2011
   Google Scholar